The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

Tom Nolan reviews this week’s research Exercise for 30 minutes three times a week on an exercise bike for a month; then make the sessions an hour long and add resistance training with two sets of ...

In October 2023, it signed an agreement with Diakonos Oncology to develop a cell therapy, DOC1021, to treat glioblastoma ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...

There is a point every year at which my embrace of winter erodes – e.g., “I’ve had it with winter” and the beauty of the ...

People with pockets of fat hidden within their muscles have a higher risk of dying from heart-related health problems, ...

The staff of Chapter One Book Store share books we love, books that bent our minds, books that illuminated our souls and the ...

GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...

The rise of politically motivated violence in the United States in recent years, highlighted in the recent murder of ...

Colombia on Wednesday reinstated arrest warrants for dozens of guerrilla commanders blamed for armed attacks that displaced ...